Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KANT

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Proteostasis Therapeutics, Inc.

Business Wire August 25, 2020

PROTEOSTASIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Newsfile August 25, 2020

PROTEOSTASIS MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger of Proteostasis Therapeutics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact The Firm

PR Newswire August 25, 2020

PROTEOSTASIS THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PTI and Encourages Investors to Contact the Firm

GlobeNewswire August 24, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Proteostasis Therapeutics, Inc. and Yumanity Therapeutics, Inc. is Fair to PTI Shareholders

Newsfile August 24, 2020

Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement

PR Newswire August 24, 2020

Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results

PR Newswire August 6, 2020

Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

PR Newswire June 5, 2020

Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

PR Newswire June 1, 2020

Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

PR Newswire May 15, 2020

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

PR Newswire May 13, 2020

Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board

PR Newswire April 13, 2020

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

PR Newswire March 10, 2020

Proteostasis Therapeutics Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis

PR Newswire February 25, 2020

Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis

PR Newswire February 24, 2020

Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients

PR Newswire January 22, 2020

Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA

PR Newswire January 13, 2020

Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients

PR Newswire December 17, 2019

Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

PR Newswire December 11, 2019

Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

PR Newswire December 3, 2019